Biomerica (BMRA) Stock Price, News & Analysis

Company Overview

Biomerica, Inc. (NASDAQ:BMRA) is a life sciences company specializing in the development, manufacture and commercialization of in vitro diagnostic tests and medical devices. The company’s core business activities encompass gastrointestinal health, diabetes management, cardiovascular wellness and cancer risk assessment. Biomerica’s product portfolio includes immunoassay kits, point-of-care analyzers, test strips and reagent sets that support early detection and monitoring of chronic and acute health conditions.

Founded in 1976 and headquartered in Irvine, California, Biomerica has grown from a regional diagnostics supplier into a global provider with distribution channels spanning North America, Europe, Latin America and Asia. The company maintains quality management systems in compliance with ISO 13485 standards, and many of its products carry CE marking for sale in the European Union. Biomerica’s manufacturing operations leverage partnerships with contract manufacturers in Asia and Europe to ensure scalability and cost efficiency.

Among its flagship offerings are gastrointestinal marker tests designed to detect conditions such as celiac disease, Helicobacter pylori infection and pancreatic insufficiency. Biomerica also markets rapid glucose and ketone monitoring strips, cardiac risk panels for home and clinical settings, and novel cancer screening assays aimed at early identification of colorectal and prostate malignancies. Through ongoing research collaborations, the company invests in next-generation diagnostics, including molecular and point-of-care platforms.

Biomerica is led by an executive team with extensive experience in diagnostics and medical device industries. Under the direction of its Chief Executive Officer, the company pursues strategic partnerships and expansion initiatives to broaden its product reach and enhance clinical utility. Biomerica continues to focus on innovation, regulatory compliance and customer support to address evolving healthcare needs around the world.

Key Stats

• Today's Range: $3.09 to $3.37
• 50-Day Range: $2.99 to $3.67
• 52-Week Range: $1.93 to $10.16
• Volume: 16,228 shs
• Average Volume: 282,678 shs
• Market Capitalization: $8.44 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Biomerica Stock Analysis - MarketRank™

Biomerica scored higher than 23% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Biomerica.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Biomerica is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Biomerica is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Biomerica has a P/B Ratio of 1.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.00% of the float of Biomerica has been sold short.

Short Interest Ratio / Days to Cover

Biomerica has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biomerica has recently decreased by 13.37%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biomerica does not currently pay a dividend.

Dividend Growth

Biomerica does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.00% of the float of Biomerica has been sold short.

Short Interest Ratio / Days to Cover

Biomerica has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biomerica has recently decreased by 13.37%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

Biomerica has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.96 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Biomerica this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for BMRA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

1 people have added Biomerica to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Biomerica insiders have not sold or bought any company stock.

Percentage Held by Insiders

15.00% of the stock of Biomerica is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 22.28% of the stock of Biomerica is held by institutions.

BMRA Stock Analysis - Frequently Asked Questions

How have BMRA shares performed this year?

Biomerica's stock was trading at $2.4008 at the beginning of the year. Since then, BMRA stock has increased by 32.5% and is now trading at $3.18.

How were Biomerica's earnings last quarter?

Biomerica, Inc. (NASDAQ:BMRA) announced its quarterly earnings data on Monday, April, 14th. The company reported ($0.48) earnings per share (EPS) for the quarter. The firm had revenue of $1.12 million for the quarter. Biomerica had a negative trailing twelve-month return on equity of 85.90% and a negative net margin of 85.42%.

When did Biomerica's stock split?

Shares of Biomerica reverse split before market open on Monday, April 21st 2025.The 1-8 reverse split was announced on Wednesday, April 16th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 18th 2025. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

How do I buy shares of Biomerica?

Shares of BMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Biomerica own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Biomerica investors own include Pfizer (PFE), Gilead Sciences (GILD), AT&T (T), NIO (NIO), Exxon Mobil (XOM), Avino Silver & Gold Mines (ASM) and Bristol Myers Squibb (BMY).

Company Calendar

• Last Earnings: 4/14/2025
• Today: 7/17/2025
• Next Earnings (Estimated): 8/26/2025
• Fiscal Year End: 5/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BMRA
• CIK: 73290
• Web: www.biomerica.com
• Phone: (949) 645-2111
• Fax: 949-553-1231
• Employees: 60
• Year Founded: 1971

Profitability

• EPS (Trailing Twelve Months): ($2.32)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$5.98 million
• Net Margins: -85.42%
• Pretax Margin: -85.35%
• Return on Equity: -85.90%
• Return on Assets: -61.06%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.76
• Quick Ratio: 2.76

Sales & Book Value

• Annual Sales: $5.41 million
• Price / Sales: 1.48
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.13 per share
• Price / Book: 1.01

Miscellaneous

• Outstanding Shares: 2,550,000
• Free Float: 2,164,000
• Market Cap: $8.03 million
• Optionable: Optionable
• Beta: 0.35